Contact Online Pharmacycheap Online PharmacyAbout Online Pharmacy

Weight Loss
Hoodia
Phentramin
Acompliex
Xenical

Weight Loss predicts mortality after recurrent oral cavity and oropharyngeal carcinomas.

BACKGROUND: The prognosis of patients with recurrent tumors of the head and neck generally is considered poor. Better prediction of outcomes can help physicians counsel patients about the merits of additional treatment. The TNM system, which was created for patients with primary tumors, may not provide optimal information. Anatomic staging systems traditionally have ignored symptom-based variables, such as weight loss, despite their known prognostic value. The objectives of this study were 1) to measure the prognostic impact of weight loss, 2) to evaluate the prognostic value of the TNM staging system, and 3) to create a practical staging system capable of predicting survival after patients develop recurrent tumors of the oral cavity and oropharynx. METHODS: A retrospective chart review was used to identify an inception cohort of patients seeking treatment for recurrent, persistent, and second primary tumors of the oral cavity and oropharynx at the University of Washington. The primary outcome variable was 1-year survival. RESULTS: The 1-year survival rate for the cohort (n = 97 patients) was 38%, with a median survival of 0.7 years. Multivariate analysis (Cox regression) identified weight loss, previous radiation to the head and neck, and TNM stage of the recurrent tumor as factors that had a substantial impact on mortality. A second multivariate technique called conjunctive consolidation was used to determine the relative quantitative impact of each variable on survival and to develop a clinical staging system. weight loss and previous radiation had the greatest influence, and the use of just these two variables resulted in a three-tiered staging system with 1-year survival rates of 62% (16 of 26 patients), 44% (18 of 41 patients), and 10% (3 of 30 patients). In contrast, the TNM staging system produced survival rates of 60% (patients with Stage I disease), 67% (patients with Stage II disease), 32% (patients with Stage III disease), and 32% (patients with Stage IV disease). CONCLUSIONS: The authors found substantial variation in survival after patients developed recurrent tumors of the oral cavity and oropharynx. Two readily available clinical variables--weight loss and previous radiation--were combined to create a clinically practical staging scheme with more prognostic power than the TNM staging system. Until molecular markers can reliably used be to predict outcomes, greater attention needs to be given to the utility of simple, inexpensive, and surprisingly powerful clinical variables. Copyright 2002 American Cancer Society.

Left ventricular function and cardiopulmonary performance following surgical treatment of morbid obesity.

BACKGROUND: It is well established that morbid obesity affects the respiratory system and the diastolic function of the heart. During exercise, cardiopulmonary reserve is exhausted because of augmented requirements, leading to a significant intolerance. A study was undertaken to investigate the influence of body weight loss on the characteristics of the left ventricle (LV) and on exercise capacity in obese patients before and 6 months, following vertical banded gastroplasty (VBG). METHODS: 16 morbidly obese individuals (BMI > 40 kg/m2) scheduled for VBG were studied. A symptom-limited cardiopulmonary exercise test and a complete transthoracic echocardiogram were performed 1 day before operation and 6 months postoperatively (after the patients achieved a body weight loss of > 20% of their pre-operative values). RESULTS: Exercise duration increased significantly 6 months following surgery. The mean O2 consumption at peak exercise (peak VO2) and at the anaerobic threshold (VO2AT) was significantly higher after weight loss. 6 months after VBG the LV thickness decreased significantly. Regarding the diastolic indices, isovolumic relaxation time (IVRT) and early/late (E/A) velocity ratio, there was a significant improvement after weight loss. Simple linear regression analysis revealed that peak VO2 and VO2AT were significantly correlated with IVRT and E/A velocity ratio. CONCLUSIONS: weight loss after VBG improves the cardiac diastolic function and this is associated with an improvement in cardiopulmonary exercise performance. Left ventricular filling variables could be considered among the most important determinants of exercise intolerance in obese individuals.

Laparoscopic adjustable gastric banding: surgical technique.

Laparoscopic adjustable gastric banding is an effective and safe surgical treatment for morbid obesity. Initial experience with the Lap-Band system (Inamed Health, Santa Barbara, California) in the United States and Australia has demonstrated that surgical technique can affect outcomes in terms of weight loss, quality of life, and complication rates. Placement of the gastric band by means of the perigastric technique is associated with high rates of gastric prolapse, food intolerance, and weight loss failure that frequently lead to band explantation. In the pars flaccida technique, band placement higher on the stomach results in the formation of a smaller pouch and lower rates of gastric prolapse, which may contribute to greater weight loss and improved quality of life. This article describes the technical aspects of the pars flaccida approach in the laparoscopic placement of adjustable gastric bands.

Effect of weight loss on muscle lipid content in morbidly obese subjects.

The purpose of this study was to test the hypothesis that weight loss results in a reduction in intramuscular lipid (IMCL) content that is concomitant with enhanced insulin action. Muscle biopsies were obtained from morbidly obese individuals [body mass index (BMI) 52.2 +/- 2.5 kg/m(2); n = 6] before and after gastric bypass surgery, an intervention that improves insulin action. With intervention, there was a 47% reduction (P < 0.01) in BMI and a 93% decrease in homeostasis model assessment, or HOMA (7.0 +/- 1.9 vs. 0.5 +/- 0.1). Histochemically determined IMCL content decreased (P < 0.05) by approximately 30%. In relation to fiber type, IMCL was significantly higher in type I vs. type II fibers. In both fiber types, there were reductions in IMCL and trends for muscle atrophy. Despite these two negating factors, the IMCL-to-fiber area ratio still decreased by approximately 44% with weight loss. In conclusion, despite differing initial levels and possible atrophy, weight loss appears to decrease IMCL deposition to a similar relative extent in type I and II muscle fibers. This reduction in intramuscular triglyceride may contribute to enhanced insulin action seen with weight loss.

Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal.

BACKGROUND: Despite the popularity of antiobesity medications, there is a lack of population-based data on their use. In addition, response (termination of pill use and receipt of an echocardiogram) to the fenfluramine and dexfenfluramine market withdrawal among the public has not been described. Lessons learned from this event have implications for future withdrawals. METHODS: We used data from the Behavioral Risk Factor Surveillance System (BRFSS) a random-digit telephone survey. In 1998, six states included detailed questions about the use of prescription weight loss pills in the previous 2 years, n = 16,460 noninstitutionalized adults aged 18 years or older. RESULTS: Almost one third of prescription weight loss pills users were not obese before taking pills. Family and friends and other nonphysicians were reported as sources of medication by one in ten users. One third of users also reported taking nonprescription diet products. Among fenfluramine or dexfenfluramine users, one third continued pill use after the market withdrawal and only one quarter received echocardiograms. CONCLUSIONS: Despite enormous publicity, many persons continued to use fen-phen after the market withdrawal and most did not receive follow-up echocardiograms. Our study raises issues regarding the effectiveness of withdrawal warnings in a small but significant subset. Additional means of communicating risk to individuals are needed for future product withdrawals including special strategies for those lacking healthcare coverage.

Herbal weight-loss supplement misadventures per a regional poison center.

BACKGROUND: Many herbal supplements used for weight loss contain stimulants. The poison control center has noted an increase in reports of adverse events with intentional and unintentional ingestion of herbal weight-loss supplements. OBJECTIVE: To identify characteristics of the callers (eg, demographic properties, underlying type of ingestion) and, from this information, determine populations at increased risk for adverse events secondary to intentional and unintentional herbal weight-loss supplement ingestion. METHODS: Demographic information such as patient weight, age, gender, and medical history was recorded from ingestions reported to the Central Ohio Poison Control Center (COPC) in 2000. Ingredients, concurrent medications, ingestion and treatment site, clinical presentation, and therapies received were documented. Type of ingestion, acuity, clinical presentation, and treatment site were used to identify patients at increased risk of adverse events secondary to herbal supplement ingestion. RESULTS: Eighty calls were recorded in 2000 (49 females involved). Underlying reasons for ingestion differed between males and females (p = 0.025). Twenty-five percent of the intentional ingestions and 51% of the unintentional ingestions occurred in males. Reported symptoms differed with the underlying reason for ingestion (p < or = 0.001) and were more common in intentional ingestions (80%). Symptoms were reported more often with unknown or higher-than-recommended doses (78%); however, 70% (n = 10) of subjects ingesting the recommended dose reported at least one symptom (p = 0.15). CONCLUSIONS: Intentional and unintentional ingestions of herbal supplements for weight loss vary with age and gender. The significant presence of symptoms in nonabusers requires more study to assess overall safety and potential toxicity of agents such as Stacker 2. Patients who abuse or misuse herbal weight-loss supplements are generally women, who may seek medical treatment more often.

Postoperative management of laparoscopic gastric banding.

BACKGROUND: The authors investigated the postoperative management of morbidly obese patients treated by laparoscopic adjustable gastric banding (LAGB) with the Lap-Band System. METHODS: The 3-year postoperative band management is presented in 379 morbidly obese patients, divided according to intra-operative band filling and quartiles of maximum postoperative band filling. RESULTS: LAGB resulted in a 40.8 +/- 24.5 percent excess weight loss (%EWL). Stoma stenosis occurred in 87 patients (23.0%), pouch dilatation in 52 (13.7%) and esophageal dilatation in 22 (5.8%). Most band-related complications were controlled by simple band deflation. The mean number of postoperative band adjustments was 2.3 +/- 1.7, and mean maximum band filling after surgery was 2.8 +/- 1.2 ml. weight loss at 3 years was identical in 205 patients who had the band completely unfilled at surgery and in 174 patients who had the band filled with 1 to 3 ml of sterile saline. The rate of band-related complications was significantly lower in the first group. No differences in %EWL were observed between quartiles of maximum band filling after surgery. The rate of band-related complications increased with increasing levels of postoperative maximum band filling. In patients with the band filled with < 3.0 ml of sterile saline at 6 months, the inflation of further saline produced a dose-related increase in the rate of weight loss. In patients with the band filled with > 3.0 ml of sterile saline at 6 months, the inflation of further saline was associated with a reduced %EWL. CONCLUSION: Postoperative adjustability of the Lap-Band was useful in the treatment of band-related complications and was able to significantly influence the rate of weight loss. On the other hand, aggressive postoperative band filling was associated with an increased rate of complications.

Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C.

Niemann-Pick C disease (NPC) is an irreversible neurodegenerative disorder without current treatment. It is the result of deficient intracellular cholesterol movement. We investigated the effects of tamoxifen and vitamin E (D-alpha tocopherol) treatment on patterns of weight loss and motor function in the mouse model of Niemann-Pick C disease (Npc1-/- mice). Tamoxifen has multiple metabolic effects, including reducing oxidative damage, while vitamin E primarily has this property. Npc1-/- mice were identified and treatment was initiated at an approximate age of 21 days. Tamoxifen suspended in peanut oil was administered via intraperitoneal injection (weekly, at a dose calculated to deliver 0.023 microg/g/day). Vitamin E (25 IU) was administered orally via gavage once a week. weight loss and Rota-Rod performance were analyzed by using Kaplan-Meyer survival curves. Tamoxifen treatment by itself significantly delayed weight loss (an endpoint of neurodegeneration) in male and female mice compared to untreated controls. Motor function was evaluated by performance on a Rota-Rod. Tamoxifen maintained Rota-Rod performance for about an extra week. Vitamin E treatment significantly delayed weight loss in females only. Rota-Rod performance was maintained slightly longer in mice treated with vitamin E. Simultaneous use of both treatments did not delay weight loss longer than tamoxifen-only treatment but had a greater effect than either treatment alone on Rota-Rod performance and demonstrated a significant positive effect on the early "learning curve" portion of the Rota-Rod evaluations. We found significant but relatively small improvements in rate of disease progression by treating Npc1-/- mice with tamoxifen and/or vitamin E. Some sex differences in response and an early improvement in Rota-Rod performance suggest areas for further study.

 

weight loss diet pills pharmacy 1 | weight loss diet pills pharmacy 2 | weight loss diet pills pharmacy 3 | weight loss diet pills pharmacy 4 | weight loss diet pills pharmacy 5 | weight loss diet pills pharmacy 6 | weight loss diet pills pharmacy 7 | weight loss diet pills pharmacy 8 | weight loss diet pills pharmacy 9 | weight loss diet pills pharmacy 10 | weight loss diet pills pharmacy 11 | weight loss diet pills pharmacy 12 | weight loss diet pills pharmacy 13 | weight loss diet pills pharmacy 14 | weight loss diet pills pharmacy 15 | weight loss diet pills pharmacy 16 | weight loss diet pills pharmacy 17 | weight loss diet pills pharmacy 18 | weight loss diet pills pharmacy 19 | weight loss diet pills pharmacy 20 | weight loss diet pills pharmacy 21 | weight loss diet pills pharmacy 22 | weight loss diet pills pharmacy 23 | weight loss diet pills pharmacy 24 | weight loss diet pills pharmacy 25 | weight loss diet pills pharmacy 26 | weight loss diet pills pharmacy 27 | weight loss diet pills pharmacy 28 | weight loss diet pills pharmacy 29 | weight loss diet pills pharmacy 30 | weight loss diet pills pharmacy 31 | weight loss diet pills pharmacy 32 | weight loss diet pills pharmacy 33 | weight loss diet pills pharmacy 34 | weight loss diet pills pharmacy 35 | weight loss diet pills pharmacy 36 | weight loss diet pills pharmacy 37 | weight loss diet pills pharmacy 38 | weight loss diet pills pharmacy 39 | weight loss diet pills pharmacy 40 | weight loss diet pills pharmacy 41 | weight loss diet pills pharmacy 42 | weight loss diet pills pharmacy 43 | weight loss diet pills pharmacy 44 | weight loss diet pills pharmacy 45 | weight loss diet pills pharmacy 46 | weight loss diet pills pharmacy 47 | weight loss diet pills pharmacy 48 | weight loss diet pills pharmacy 49 | weight loss diet pills pharmacy 50 | weight loss diet pills pharmacy 51 | weight loss diet pills pharmacy 52 | weight loss diet pills pharmacy 53 | weight loss diet pills pharmacy 54 | weight loss diet pills pharmacy 55 | weight loss diet pills pharmacy 56 | weight loss diet pills pharmacy 57 | weight loss diet pills pharmacy 58 | weight loss diet pills pharmacy 59 | weight loss diet pills pharmacy 60 | weight loss diet pills pharmacy 61 | weight loss diet pills pharmacy 62 | weight loss diet pills pharmacy 63 | weight loss diet pills pharmacy 64 | weight loss diet pills pharmacy 65 | weight loss diet pills pharmacy 66 | weight loss diet pills pharmacy 67 | weight loss diet pills pharmacy 68 | weight loss diet pills pharmacy 69 | weight loss diet pills pharmacy 70 | weight loss diet pills pharmacy 71 | weight loss diet pills pharmacy 72 | weight loss diet pills pharmacy 73 | weight loss diet pills pharmacy 74 | weight loss diet pills pharmacy 75 | weight loss diet pills pharmacy 76 | weight loss diet pills pharmacy 77 | weight loss diet pills pharmacy 78 | weight loss diet pills pharmacy 79 | weight loss diet pills pharmacy 80 | weight loss diet pills pharmacy 81 | weight loss diet pills pharmacy 82 | weight loss diet pills pharmacy 83 | weight loss diet pills pharmacy 84 | weight loss diet pills pharmacy 85 | weight loss diet pills pharmacy 86 | weight loss diet pills pharmacy 87 | weight loss diet pills pharmacy 88 | weight loss diet pills pharmacy 89 | weight loss diet pills pharmacy 90 |
Secure Online Ordering FedEx Shipping